Weissenburger J

Weissenburger J. dysfunction, gastrointestinal complications, sleep disruption, apathy, and exhaustion, and offer approaches for management that might help sufferers achieve optimum response to pharmacotherapy. OSMI-4 2004;65:959C965. [PubMed] [Google Scholar] 2. Bull SA., Hu XU., Hunkeler EM., et al. Discontinuation useful and switching of antidepressants: impact of patient-physician conversation. . 2002;288:1403C1409. [PubMed] [Google Scholar] 3. Demyttenaere K., Enzlin P., Dewe W., et al. Conformity with antidepressants within a principal care setting up I: beyond insufficient efficiency and adverse occasions. . 2001;62(suppl 22):30C33. [PubMed] [Google Scholar] 4. Wisniewski SR., Hurry AJ., Balasubramani GK., Trivedi MH., Nierenberg AA. Self-rated global way of OSMI-4 measuring the frequency, burden and intensity of unwanted effects. . 2006;12:71C79. [PubMed] [Google Scholar] 5. Clyde DJ. SAFTEE: data program for side-effect assessment range. . 1986;22:287. [PubMed] [Google Scholar] 6. Nelson JC., Jatlow Anpep P., Quinlan DM. Subjective unwanted effects during desipramine treatment. . 1984;41:55C59. [PubMed] [Google Scholar] 7. Hurry AJ. Giles DE. Schlesser MA. Fulton CL. Weissenburger J. Burns C. The Inventory for Depressive Symptomatology (IDS): primary results. OSMI-4 . 1986;18:65C87. [PubMed] [Google Scholar] 8. Lin EHB., Von Korff M., Katon W., et al. The function of the principal care doctor in sufferers’ adherence to antidepressant therapy. . 1995;33:67C74. [PubMed] [Google Scholar] 9. Papakostas Gl. Restrictions of modern antidepressants:tolerability. . 2007;68(suppl 10):11C17. [PubMed] [Google Scholar] 10. Bull SA., Hunkeler EM., Lee JY., et al. Discontinuation or switching selective serotonin-reuptake inhibitors. . 2002;36:578C584. [PubMed] [Google Scholar] 11. Hunter AM. Make IA. Leuchter AF. The guarantee from the quantitative electroencephalogram being a predictor of antidepressant treatment final results in main depressive disorder. [122 refs] . 2007;30:105C124. Review. [PubMed] [Google Scholar] 12. losifescu DV., Renshaw PF., Lyoo IK., et al. Human brain white-matter treatment and OSMI-4 hyperintensites final result in main depressive disorder. . 2006;188:180C185. [PubMed] [Google Scholar] 13. Trindade D., Menon D., Topfer L., Coloma C. Undesireable effects connected with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. . 1998;159:1245C1252. [PMC free of charge content] [PubMed] [Google Scholar] 14. Papakostas Gl., Nutt DJ., Hallett LA., et al. Quality of sleepiness and exhaustion in main depressive disorder: an evaluation of bupropion as well as the selective serotonin reuptake inhibitors. . 2006;60:1350C1355. [PubMed] [Google Scholar] 15. Papakostas Gl., Nelson JC., Kasper S., Moller HJ. A meta-analysis of scientific trials evaluating reboxetine, a norepinephrine reuptake inhibitor with selective serotonin reuptake inhibitors for the treating main depressive disorder. . 2008;18:122C127. [PubMed] [Google Scholar] 16. Baldwin DS., Hawley CJ., Abed RT., et al. A multicenter double-blind evaluation of paroxetine and nefazodone in the treating outpatients with moderate-to-severe depression. . 1996;58(suppl 2):46C52. [PubMed] [Google Scholar] 17. Feiger A., Kiev A., Shrivastava RK., et al. Nefazodone versus sertraline in outpatients with main depression: concentrate on efficiency, tolerability, and results on intimate satisfaction and function. . 1996;57(suppl 2):53C62. [PubMed] [Google Scholar] 18. Berlanga C., Arechavaleta B., Heinze G., et al. A double-blind evaluation of fluoxetine and nefazodone in the treating despondent outpatients. . 1997;20:1C8. [Google Scholar] 19. Montgomery SA., Huusom AK., Bothmer J. A randomized research evaluating escitalopram with venlafaxine XR in principal care sufferers with main depressive disorder. . 2004;50:57C64. [PubMed] [Google Scholar] 20. Bielski RJ., Ventura D., Chang OSMI-4 CC. A double-blind evaluation of venlafaxine and escitalopram extended release in the treating main depressive disorder. . 2004;65:1190C1196. [PubMed] [Google Scholar] 21. Schatzberg A., Roose S. A double-blind, placebo-controlled study of fluoxetine and venlafaxine in geriatric outpatients with main depression. . 2006;14:361C370. [PubMed] [Google Scholar] 22. Nelson JC., Prtichett YL., Martynov O., et al. The basic safety and tolerability of duloxetine weighed against paroxetine and placebo: a pooled evaluation of 4 scientific studies. . 2006;8:212C219. [PMC free of charge content] [PubMed] [Google Scholar] 23. Goldstien DJ., Mallinckrodt.

Related Posts